AI-generated research brief — verify at source
Pimicotinib Achieves 54% Response Rate in Unresectable TGCT Phase 3 Trial
In a randomised, placebo-controlled phase 3 trial, pimicotinib produced an objective response rate of 54% compared with 3% for placebo in patients with unresectable, symptomatic tenosynovial giant cell tumour — an absolute difference of 51 percentage points (95% CI 33–63, p<0.0001). The magnitude of this treatment effect, combined with a largely manageable adverse event profile, positions pimicotinib as a meaningful systemic option for a condition with very limited alternatives.
What Was Studied
The MANEUVER trial investigated whether pimicotinib — a highly selective and potent inhibitor of colony-stimulating factor-1 receptor (CSF-1R) — could safely and effectively reduce tumour burden and symptoms in adults with tenosynovial giant cell tumour (TGCT), a rare locally aggressive neoplasm that currently has few systemic treatment options despite its significant impact on mobility and quality of life.
How It Was Studied
This international, double-blind, randomised, placebo-controlled phase 3 study enrolled patients aged 18 years or older across 40 specialised hospitals in Asia, Europe, and North America between April 2023 and March 2024. A total of 94 patients with unresectable, symptomatic TGCT — defined by a patient-reported worst stiffness or worst pain score of at least 4 out of 10 — were randomised 2:1 to receive either oral pimicotinib 50 mg once daily (n=63) or a visually identical placebo (n=31) for 24 weeks. Randomisation was stratified by region (China versus non-China), and all patients, investigators, and study funders remained masked to treatment assignment throughout Part 1. Patients completing Part 1 were eligible to continue into open-label Part 2, during which placebo recipients could cross over to active treatment.
What Was Observed
- Pimicotinib produced a substantially higher objective response rate at week 25 compared with placebo: 54% (34 of 63 patients) versus 3% (1 of 31 patients), representing an absolute difference of 51 percentage points (95% CI 33–63, p<0.0001). This difference is highly unlikely to be due to chance and reflects a robust antitumour signal.
- The safety profile was dominated by mild, largely manageable adverse events. The most commonly reported clinical events in the pimicotinib group included pruritus, facial oedema, rash, periorbital oedema, and fatigue — consistent with the CSF-1R inhibitor class mechanism. Notably, no cholestatic hepatotoxicity, drug-induced liver injury, or skin or hair hypopigmentation was observed.
- The only grade 3 or 4 treatment-emergent adverse event occurring in more than 10% of pimicotinib-treated patients was an asymptomatic elevation in blood creatine phosphokinase, affecting 8 of 63 patients (13%). Treatment was well-tolerated overall, with dose reductions required in only 5 patients (8%) and just one discontinuation (2%).
- The investigators reported clinically meaningful improvements in TGCT-related functional limitations and symptom burden in the pimicotinib group, consistent with the high objective response rate, although specific patient-reported outcome data were not detailed numerically in the abstract.
Why This Matters
TGCT affects otherwise healthy adults and can cause substantial pain, stiffness, and joint destruction; yet systemic treatment choices remain extremely limited, representing a clear unmet need. A 51-percentage-point absolute improvement in objective response rate over placebo in a phase 3 setting is a strong efficacy signal, particularly for a rare tumour type where meaningful trial evidence is scarce. The absence of hepatotoxicity and hypopigmentation — adverse events associated with earlier CSF-1R inhibitors — may distinguish pimicotinib’s tolerability profile within this drug class.
How to Read This Result
While the effect size is compelling, the trial enrolled only 94 patients across a geographically diverse population, and the 24-week primary endpoint window does not yet address long-term durability of response or sustained safety beyond this period.
Limitations
The abstract does not explicitly report study limitations. However, the relatively small sample size (94 patients total), the short primary evaluation window of 24 weeks, and the fact that missing data were not imputed — meaning only observed data were analysed — are methodological considerations that readers should weigh when interpreting the findings.